Der Miner von Kryptowährungen setzt auf ökologische Effizienz und baut seine Rechenzentren direkt in bereits ...
Resverlogix Appoints Kenneth J. Zuerblis to Board of Directors
Calgary, Canada (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announces that Mr. Kenneth Zuerblis has been appointed to the Company's Board of Directors. Recently Mr. Zuerblis served as the Chief Financial Officer and Senior Vice President of ImClone Systems Inc., prior to its acquisition by Eli Lilly.
"I was initially attracted to Resverlogix because of RVX-208, its novel atherosclerosis drug, which is a very exciting mid-stage therapeutic gaining worldwide scientific acceptance. Resverlogix is also developing a pipeline of novel therapeutics in several disease categories that have significant unmet medical needs. I look forward to this opportunity to work with members of the Board of Directors and management as we develop the full potential of the Company's product candidates," Mr. Zuerblis commented.
Donald J. McCaffrey, President & CEO of Resverlogix, stated, "Ken is a seasoned veteran in the biotechnology industry with a proven track record of running complex commercial and research organizations and we are delighted that he has joined our Board of Directors." In an effort to maintain a Board of Director level at six people Mr. Wayne Chiu will be stepping down from the Board effective today. Wayne has been on the Board since its inception and has been an important contributor to the growth and development of Resverlogix. The Board expresses its thankfulness to Wayne for his years of contributions.
Kenneth J. Zuerblis biography
Mr. Zuerblis previously served as Chief Financial Officer and Senior Vice President of ImClone Systems, a biopharmaceutical company developing biologic medicines in the area of oncology, from 2008 through 2009 at which time he helped lead the sale of the company to Eli Lilly for $6.6 billion USD. Prior to joining ImClone, Mr. Zuerblis served as Chief Financial Officer of Enzon Pharmaceuticals Inc. from 1994 through 2005 and Corporate Controller from 1991 through 1994. He began his career at KPMG, LLP, in 1982, ultimately serving as Senior Manager prior to his departure in 1991. Mr. Zuerblis previously served as a member of the Board of Directors of XTL Biopharmaceuticals, Ltd., and is a member of the Board of Directors of Immunomedics and the New Jersey Technology Council. He received a BS in Accounting from Seton Hall University and is a certified public accountant in the State of New Jersey.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-1. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange . For further information please visit http://www.resverlogix.com.
This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at http://www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the July 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.
For further information: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., Phone: +1-403-254-9252, Email: Theresa@resverlogix.com; US Institutional Investors: Susan Noonan, Managing Partner, S.A. Noonan Communications, LLC, Phone: +1-212-966-3650, Email: Susan@sanoonan.com
ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.ch
CONTACT: For further information: Theresa Kennedy, VP,
CorporateCommunications, Resverlogix Corp., Phone: +1-403-254-9252,
Email:Theresa@resverlogix.com; US Institutional Investors: Susan
Noonan, ManagingPartner, S.A. Noonan Communications, LLC, Phone: